雜志介紹

Acs Infectious Diseases雜志介紹

《Acs Infectious Diseases》是一本以English為主的開放獲取國際優(yōu)秀期刊，中文名稱Acs 傳染病，本刊主要出版、報道醫(yī)學(xué)-CHEMISTRY, MEDICINAL領(lǐng)域的研究動態(tài)以及在該領(lǐng)域取得的各方面的經(jīng)驗和科研成果，介紹該領(lǐng)域有關(guān)本專業(yè)的最新進展，探討行業(yè)發(fā)展的思路和方法，以促進學(xué)術(shù)信息交流，提高行業(yè)發(fā)展。該刊已被國際權(quán)威數(shù)據(jù)庫SCIE收錄，為該領(lǐng)域相關(guān)學(xué)科的發(fā)展起到了良好的推動作用，也得到了本專業(yè)人員的廣泛認可。該刊最新影響因子為4，最新CiteScore 指數(shù)為9.7。

本刊近期中國學(xué)者發(fā)表的論文主要有：

• Formulation and Evaluation of Lipidized Imiquimod as an Effective Adjuvant

  Author: Yin, Wenzhu; Deng, Bihua; Xu, Zeyu; Wang, Haiyan; Ma, Fang; Zhou, Mingxu; Lu, Yu; Zhang, Jinqiu

• Identification and Molecular Modification of Staphylococcus aureus Bacteriophage Lysin LysDZ25

  Author: Chang, Yan; Li, Qingbin; Zhang, Shuhang; Zhang, Qing; Qi, Qingsheng; Lu, Xuemei; Liu, Yuqing

• Pseudolaric Acid B Ameliorates Fungal Keratitis Progression by Suppressing Inflammation and Reducing Fungal Load

  Author: Yin, Min; Li, Na; Zhang, Lina; Lin, Jing; Wang, Qian; Gu, Lingwen; Zheng, Hengrui; Zhao, Guiqiu; Li, Cui

• Long-Term Immunogenicity and In Vitro Prophylactic Protective Efficacy of M. tuberculosis Fusion Protein DR2 Combined with Liposomal Adjuvant DIMQ as a Boosting Vaccine for BCG

  Author: Wang, Xiao-chun; Xu, Li-fa; Zhang, Yan-peng; Mao, Li-rong; Du, Jian-peng; Sun, Qi-shan; Shi, Zi-lun; Xing, Ying-ru; Su, Yi-xin; Wang, Sheng-jian; Wang, Jian; Ma, Ji-lei; Zhang, Jing-yan

英文介紹

Acs Infectious Diseases雜志英文介紹

ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:

* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.

* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.

* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.

* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.

* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.

* Small molecule vaccine adjuvants for infectious disease.

* Viral and bacterial biochemistry and molecular biology.